News & Events

BREXIT

billev-pharma-east--placeholder--news

Billev Pharma East is prepared and up to date to support you with the regulatory and pharmacovigilance implications related to ‘hard’ BREXIT, being part of the task force. European Commission and CMDh already published the notice that Industry should start taking actions to be ready for worst case and to expect a hard separation in March 2019 without any transitional arrangements. Billev Pharma East has years of experiences in creating the best solutions from cost and time perspective. After taking Billev Pharma East on board we will immediately assess the Impact for you and prepare the best Regulatory strategy to meet the deadline.

Don’t miss out

Follow us on LinkedIn

Watch our
promotional video

HOME

SERVICES

Regulatory Affairs

PharmacoVigilance

Medical Consultancy

Quality / GxP

Digital Consultancy

TEAM OF EXPERTS

ABOUT US

NEWS AND EVENTS

B2B PARTNER LOG-IN